Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D1038 | paricalcitol

Molecular Formula C27H44O3
Molecular Weight 416.6
Structure
State solid
Clearance * 1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis] * 1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]
Volume of distribution * 30.8 ± 7.5 L [CKD Stage 5-HD] * 34.9 ± 9.5 L [CKD Stage 5-PD] * 23.8 L [healthy subjects]
Route of elimination Paricalcitol is excreted primarily by hepatobiliary excretion.
Protein binding 99.8% (bound to plasma proteins)
Half life 4 to 6 hours
Absorption Well absorbed

H

H05BX02 Paricalcitol


[H05BX] Other anti-parathyroid agents


[H05B] ANTI-PARATHYROID AGENTS


[H05] CALCIUM HOMEOSTASIS


[H] Systemic hormonal preparations, excluding reproductive hormones and insulins

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 8.91±1.56 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL human HepG2 MMP assay Negative IC50 163
MEMBRANE POTENTIAL rat hepatocytes MMP assay Negative IC50 163

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 140 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H300 (72.86%): Fatal if swallowed [Danger Acute toxicity, oral]


H301+H311 (27.14%): Toxic if swallowed or in contact with skin [Danger Acute toxicity, oral


acute toxicity, dermal]


H301 (27.14%): Toxic if swallowed [Danger Acute toxicity, oral]


H311 (98.57%): Toxic in contact with skin [Danger Acute toxicity, dermal]


H330 (27.14%): Fatal if inhaled [Danger Acute toxicity, inhalation]


H351 (68.57%): Suspected of causing cancer [Warning Carcinogenicity]


H361 (72.86%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


H362 (67.14%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]


H372 (27.14%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P260, P263, P264, P270, P271, P280, P281, P284, P301+P310, P302+P352, P304+P340, P308+P313, P310, P312, P314, P320, P321, P322, P330, P361, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • (1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
    (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol
    1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-; 131918-61-1 19-Nor-1,25-(OH)2D2
    19-Nor-1,25-dihydroxyvitamin D2 19-Nor-1-alpha,25-dihydroxyvitamin D2 19-Nor-1alpha,25-dihydroxyvitamin D2
    19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)- 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E) 6702D36OG5
    918P611 ABT-358 ACT07192
    AKOS005145562 Ab 122358 BCP9001050
    BDBM233195 BIDD:GT0330 BPKAHTKRCLCHEA-UBFJEZKGSA-N
    C08127 CAS-131918-61-1 CHEBI:7931
    CHEMBL1200622 CS-0705 Compound 49510
    Compound-49510 D00930 DB00910
    DSSTox_CID_28566 DSSTox_GSID_48640 DSSTox_RID_82838
    DTXSID4048640 GTPL2791 HSDB 7360
    HY-50919 LMST04030163 LS-172812
    NCGC00182706-01 Paracalcin Paricalcitol
    Paricalcitol (JAN/USAN/INN) Paricalcitol [USAN:USP:INN] Paricalcitol [USAN]
    Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin PubChem18825 Q155746
    SC-20905 SCHEMBL3655 Tox21_112987
    UNII-6702D36OG5 W-5365 ZINC13911941
    Zemplar Zemplar (TN)

    DrugBank DB00910
    CAS Number 131918-61-1, 3430-22-6
    PubChem Compound 5281104
    KEGG Compound ID C08127
    KEGG Drug D00930
    ChEBI 7931